HDMX-Selective Stapled Peptides for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting HDM2 often face resistance due to HDMX's ability to bind and sequester p53, leading to reduced efficacy, and there are no selective small molecule or stapled peptide inhibitors of HDMX with clinical development potential.
Innovation Solution
Development of HDMX-selective peptides and stapled peptides based on the p53 transactivation domain that preferentially bind to HDMX over HDM2, utilizing specific amino acid substitutions and structural stabilization to enhance binding affinity, allowing for targeted cancer therapy and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HDM2-targeting therapies are used, then p53 levels increase in certain tumors, but resistance develops due to HDMX binding and sequestering p53
Solution Approach 1:
The patent extracts the p53 transactivation domain and modifies it to create a peptide that selectively targets HDMX instead of HDM2. This extracted and modified peptide (e.g., sequences like LTFEEYWAQBTSAA with substitutions) specifically binds to HDMX, removing the resistance mechanism by directly counteracting HDMX's sequestration of p53.
Solution Approach 2:
The patent introduces specific amino acid substitutions at key positions (e.g., position 26 substitutions like L26A, L26E, or L26R) within the p53 transactivation domain peptide. These localized changes alter the binding specificity from HDM2 to HDMX, creating a peptide with tailored local properties that selectively inhibit HDMX while preserving p53 function.
2Measurement precision
If selective HDMX inhibitors are developed, then binding affinity to HDMX increases, but selectivity over HDM2 must be maintained
Solution Approach 1:
The patent applies localized amino acid substitutions at critical binding interface positions (particularly position 26 and surrounding residues) to differentiate binding affinity between HDMX and HDM2. These local modifications enhance HDMX binding while reducing HDM2 interaction, achieving selectivity through targeted changes rather than global sequence alterations.
Solution Approach 2:
The patent systematically varies amino acid parameters at key positions to optimize the binding affinity ratio between HDMX and HDM2. By changing parameters such as hydrophobicity, charge, and steric properties at specific residues, the peptide achieves high HDMX affinity while maintaining selectivity, as demonstrated by variants with different substitutions at position 26.
Data Source
AI summary
Disclosed herein are peptides and structurally-stabilized peptides that selectively bind to HDMX, or both HDMX and HDM2 as well as compositions comprising the same. Also provided are methods for using such peptides in the treatment and diagnosis of cancer (e.g., HDMX-expressing and/or -dependent cancers).